Keybank National Association Incyte Corp Transaction History

Keybank National Association

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 01, 2019	SELL	$73.52 - $88.7 $251,070 - $302,910	-3,415 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$63.56 - $88.17 $383,076 - $531,400	-6,027 Reduced 63.83%	3,415 $294,000
Q4 2018 Jan 30, 2019	BUY	$58.5 - $69.94 $58 - $69	1 Added 0.01%	9,442 $600,000
Q3 2018 Nov 08, 2018	SELL	$61.75 - $74.23 $200,193 - $240,653	-3,242 Reduced 25.56%	9,441 $652,000
Q2 2018 Aug 08, 2018	BUY	$60.85 - $83.98 $771,760 - $1.07 Million	12,683 New	12,683 $850,000
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $293,700 - $357,065	-3,536 Closed	0 $0
Q4 2017 Feb 08, 2018	SELL	$93.56 - $116.6 $453,578 - $565,276	-4,848 Reduced 57.82%	3,536 $335,000
Q3 2017 Nov 02, 2017	BUY	$109.15 - $138.27 $70,292 - $89,045	644 Added 8.32%	8,384 $979,000
Q2 2017 May 14, 2018	SELL	N/A	-750 Reduced 8.83%	7,740 $975,000
Q1 2017 May 14, 2018	BUY	N/A	2,001 Added 30.84%	8,490 $1.14 Million
Q4 2016 May 14, 2018	BUY	N/A	6,489	6,489 $651,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.